Lazard Asset Management
ANIP icon

Lazard Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Lazard Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-588
Closed -$46.4K – 1866
2025
Q4 		$46.4K Buy
588
+298
+103% +$25.8K ﹤0.01% 1797
2025
Q3 		$26.6K Buy
+290
New +$23.6K ﹤0.01% 1759
2025
Q1 		– Sell
-1,781
Closed -$97K – 2297
2024
Q4 		$97K Sell
1,781
-3,819
-68% -$219K ﹤0.01% 1801
2024
Q3 		$333K Sell
5,600
-1,235
-18% -$75.3K ﹤0.01% 1492
2024
Q2 		$434K Buy
+6,835
New +$444K ﹤0.01% 1254
2024
Q1 		– Sell
-3,022
Closed -$166K – 2031
2023
Q4 		$166K Hold
3,022
– – ﹤0.01% 1456
2023
Q3 		$175K Buy
3,022
+495
+20% +$28.6K ﹤0.01% 1435
2023
Q2 		$135K Buy
+2,527
New +$112K ﹤0.01% 1464
2023
Q1 		– Sell
-1,371
Closed -$55K – 2284
2022
Q4 		$55K Buy
+1,371
New +$51.5K ﹤0.01% 1758
2016
Q2 		– Sell
-65,073
Closed -$2.19M – 1039
2016
Q1 		$2.19M Buy
65,073
+3,683
+6% +$125K ﹤0.01% 599
2015
Q4 		$2.77M Buy
+61,390
New +$2.64M 0.01% 607

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Lazard Asset Management's ANIP Position: Q1 2026 in Review

Lazard Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 588 shares — an estimated $46.4K sold.

Lazard Asset Management first reported a position in ANIP in Q4 2015 and held it in 11 quarters. The position peaked at $2.77M in Q4 2015. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Lazard Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 588 ANI Pharmaceuticals shares in Q1 2026, an estimated $46.4K.
  • Lazard Asset Management first reported a position in ANI Pharmaceuticals in Q4 2015 and held it in 11 quarters.
  • Lazard Asset Management's ANI Pharmaceuticals position peaked at $2.77M in Q4 2015.
  • 281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.